How to Apply to SOSV NY and SF with Finta

If you are looking for the IndieBio application, start with the current SOSV NY and SOSV SF routes. Prepare a clear account of your technology, the evidence collected so far, the customer problem, and the next question the company must resolve. Use the current program selector rather than an old cohort page.

Source check: October 22, 2026. The former IndieBio site explains that SOSV changed the name to SOSV NY and SOSV SF in 2026. Both current location pages say applications are reviewed on a rolling basis. No fixed intake deadline or deadline timezone was confirmed for this guide.

This is an independent preparation guide from Finta. It is not an official application, endorsement, or partnership with SOSV NY and SOSV SF. The founder remains responsible for the facts and submits through the program’s own channel.

What you will be able to do

• Find the current application route behind the former IndieBio name.
• Choose a location by the work and support your company actually needs.
• Separate scientific observations, commercial assumptions and review questions in an evidence packet.

• Use the current name without losing the original reader question
• Choose a route by the next company risk
• Build a science-to-company evidence ledger
• Worked example: distinguish a material result from market readiness
• Review the packet in the same categories as the application
• Questions about the former IndieBio application

Use the current name without losing the original reader question

IndieBio’s official transition page explains the name change and the expansion of the programs’ remit beyond biology. SOSV’s current program selector distinguishes SOSV NY, SOSV SF and HAX. The NY and SF choices lead to the current SOSV application. Do not create duplicate applications simply because an old article uses IndieBio and a new page uses a location name.

Record the program and location exactly as the live form presents them. Your question is not merely which city sounds more appealing. Ask which technical facilities, commercial setting and participation arrangement match the company’s next milestone. The program must confirm fit; an editorial comparison cannot establish admission eligibility.

Choose a route by the next company risk

The NY page emphasizes technically difficult companies and scientific commercialization, including therapeutics. The SF page describes a broad deep-tech portfolio, laboratory facilities, and its current in-person expectations. These are program descriptions, not promises that a particular resource or partner will be available to your startup.

Do not present laboratory access as regulatory approval, an investment as a grant, or optional follow-on support as committed capital. Keep documents and professional-review questions separate from your product story.

Build a science-to-company evidence ledger

The application asks about the problem, technical basis, team experience, intellectual property, customers and business model. Prepare a coherent evidence ledger before attempting to compress that information into a form. The ledger below is Finta’s editorial preparation tool, not SOSV’s scoring system.

Make the limitation column useful. “More research needed” is too vague. State which part of a result may not transfer: sample type, operating environment, manufacturing scale, customer workflow or repeatability. A medical or regulatory claim needs the appropriate expert review; a writing tool cannot certify it.

Worked example: distinguish a material result from market readiness

Fictional example. LeafThread is developing a bio-derived packaging material. Its founders have tested small samples under a single laboratory condition and spoken with three packaging buyers. They have not completed industrial processing, disposal certification, or a paid pilot. This example is invented for learning and is not an SOSV company.

The draft says, “Our sustainable packaging is ready to replace plastic worldwide.” The evidence supports: “We have produced small bio-derived samples and measured their behavior under one laboratory condition. Three exploratory buyer conversations identified barrier performance and processing compatibility as questions we must test next. We have not validated industrial production or end-of-life claims.”

The revised description gives the program something concrete to evaluate without overstating environmental or commercial outcomes. The founders can use the route worksheet to ask which location is suited to the next characterization and customer-validation work. They cannot infer that a city choice confers a certification or creates demand.

A useful draft appendix would separate the sample record, the buyer notes and the plan. Each document should have an owner and a date. If a university or collaborator owns part of the work, the founder should resolve disclosure and rights with qualified help before attaching it to an application.

Review the packet in the same categories as the application

1. Give the technology a plain-language explanation that a non-specialist can follow.
2. Link each important result to a permitted source and retain the conditions and limitations.
3. Identify the primary customer and separate customer evidence from market-size assumptions.
4. Explain the relevant work each founder actually performed.
5. Check that intellectual-property statements reflect current records rather than an aspiration to file.
6. Confirm the selected program, participation constraints and document-access permissions in the live form.

For an AI review, supply a limited, authorized summary rather than unpublished raw data, restricted sequences, patient information or private collaborator records. Ask the tool to identify gaps and contradictory statements. The founder and qualified advisers remain responsible for scientific, legal and regulatory judgments.

Questions about the former IndieBio application

Is IndieBio still the application name?

The former site now explains the move to SOSV NY and SOSV SF. Start from the official selector and use the current name on your application. Old guides may still be useful historically but are not a current intake instruction.

Are these routes limited to biology?

The official transition notice says the remit has broadened to deep tech. Explain your actual technology and confirm its fit with the relevant team instead of assuming that an old label defines present eligibility.

Does completing this worksheet validate the science?

No. It organizes claims and evidence for discussion. Technical, clinical, environmental and regulatory claims require the appropriate substantive review.

This guide provides general application education. It is not scientific certification or personalized legal, medical, tax or investment advice. Consult the relevant qualified professionals before relying on consequential claims or terms.

Copyable AI prompt

Try this exercise with Aurora AI in Finta, Claude, or Codex. Provide only material you are authorized to share. The output is a draft for your review, not an application submission.

Help organize my SOSV NY/SF application evidence for founder review.
Selected current program and official instructions: [URL, location, checked date]
Problem and proposed technical mechanism: [authorized summary]
Evidence with conditions, dates and limitations: [permitted facts]
Team contributions and IP/permission questions: [facts and unknowns]
Customer observations and business assumptions: [separate lists]
Produce an evidence/limitation/commercial-question ledger, a plain-language technology explanation, drafts for the supplied current questions, and a qualified-review list. Distinguish observed results, hypotheses, scientific interpretation and commercial plans. Do not invent performance, certifications, clinical outcomes, patents, customer commitments or admissions scores. Mark unknowns. Do not disclose restricted data, contact SOSV, submit forms, or change records.

Review the work, then use the official route

Read the output against your source documents, resolve each unknown, and ask a co-founder to check the version you plan to submit. Do not send private credentials, unrestricted data-room links, or material you lack permission to share. When the content is ready, continue through SOSV NY and SOSV SF’s official application route. Finta does not submit this application for you.

For the wider program shortlist, use Finta’s startup accelerator directory. Keep application preparation separate from the broader fundraising process, including preparing for an accelerator interview when an invitation arrives.